Total Payments
$5,921
2024 Payments
$869.67
Companies
32
Transactions
346
Medicare Patients
3,101
Medicare Billing
$1.4M
Payment Breakdown by Category
Food & Beverage$5,388 (91.0%)
Other$398.80 (6.7%)
Education$134.25 (2.3%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $5,388 | 332 | 91.0% |
| Long term medical supply or device loan | $398.80 | 4 | 6.7% |
| Education | $134.25 | 10 | 2.3% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,123 | 47 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $926.81 | 43 | $0 (2024) |
| PFIZER INC. | $706.68 | 73 | $0 (2020) |
| Amgen Inc. | $545.33 | 31 | $0 (2023) |
| Kyowa Kirin, Inc. | $351.54 | 19 | $0 (2021) |
| TerSera Therapeutics LLC | $343.75 | 21 | $0 (2024) |
| PUMA BIOTECHNOLOGY, INC. | $238.55 | 16 | $0 (2021) |
| Eisai Inc. | $205.76 | 12 | $0 (2020) |
| Genentech USA, Inc. | $190.64 | 10 | $0 (2024) |
| Helsinn Therapeutics (U.S.), Inc. | $174.06 | 10 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $869.67 | 27 | Novartis Pharmaceuticals Corporation ($495.84) |
| 2023 | $223.51 | 10 | Novartis Pharmaceuticals Corporation ($69.71) |
| 2021 | $161.17 | 9 | AstraZeneca Pharmaceuticals LP ($45.78) |
| 2020 | $518.67 | 29 | PFIZER INC. ($110.42) |
| 2019 | $1,346 | 90 | AstraZeneca Pharmaceuticals LP ($246.45) |
| 2018 | $1,621 | 99 | Novartis Pharmaceuticals Corporation ($251.37) |
| 2017 | $1,181 | 82 | AstraZeneca Pharmaceuticals LP ($241.58) |
All Payment Transactions
346 individual payment records from CMS Open Payments — Page 1 of 14
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/13/2024 | Tempus AI, Inc | — | Food and Beverage | In-kind items and services | $14.71 | General |
| 12/10/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Long term medical supply or device loan | In-kind items and services | $99.70 | General |
| Category: Oncology | ||||||
| 12/05/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Food and Beverage | In-kind items and services | $13.28 | General |
| Category: Oncology | ||||||
| 11/19/2024 | AstraZeneca Pharmaceuticals LP | ENHERTU (Biological) | Food and Beverage | In-kind items and services | $25.78 | General |
| Category: Oncology | ||||||
| 11/19/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological), LYNPARZA | Food and Beverage | In-kind items and services | $15.07 | General |
| Category: ONCOLOGY | ||||||
| 11/14/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Long term medical supply or device loan | In-kind items and services | $99.70 | General |
| Category: Oncology | ||||||
| 11/12/2024 | Spectrum Pharmaceuticals Inc. | ROLVEDON (Drug) | Food and Beverage | In-kind items and services | $20.65 | General |
| Category: Oncology | ||||||
| 11/07/2024 | Genentech USA, Inc. | Itovebi (Biological) | Food and Beverage | In-kind items and services | $21.80 | General |
| Category: BioOncology | ||||||
| 11/05/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $27.29 | General |
| Category: ONCOLOGY | ||||||
| 10/24/2024 | TerSera Therapeutics LLC | Zoladex (Drug) | Food and Beverage | In-kind items and services | $20.87 | General |
| Category: Oncology | ||||||
| 10/17/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Long term medical supply or device loan | In-kind items and services | $99.70 | General |
| Category: Oncology | ||||||
| 10/04/2024 | AstraZeneca Pharmaceuticals LP | ENHERTU (Biological) | Food and Beverage | In-kind items and services | $21.62 | General |
| Category: Oncology | ||||||
| 09/27/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Long term medical supply or device loan | In-kind items and services | $99.70 | General |
| Category: Oncology | ||||||
| 09/12/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $29.79 | General |
| 08/22/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Food and Beverage | In-kind items and services | $24.92 | General |
| Category: Oncology | ||||||
| 07/11/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $24.48 | General |
| Category: ONCOLOGY | ||||||
| 06/10/2024 | AstraZeneca Pharmaceuticals LP | ENHERTU (Biological) | Food and Beverage | In-kind items and services | $14.54 | General |
| Category: Oncology | ||||||
| 05/30/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Food and Beverage | In-kind items and services | $18.50 | General |
| Category: Oncology | ||||||
| 05/28/2024 | Stemline Therapeutics Inc. | Orserdu (Drug) | Food and Beverage | In-kind items and services | $16.02 | General |
| Category: Oncology | ||||||
| 05/10/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $19.43 | General |
| 05/07/2024 | Novartis Pharmaceuticals Corporation | Fabhalta (Drug) | Food and Beverage | In-kind items and services | $23.53 | General |
| Category: Immunology | ||||||
| 05/02/2024 | Incyte Corporation | MONJUVI (Drug) | Food and Beverage | Cash or cash equivalent | $16.36 | General |
| Category: Oncology | ||||||
| 04/27/2024 | Astellas Pharma US Inc | Xospata (Drug) | Food and Beverage | In-kind items and services | $15.88 | General |
| Category: Oncology | ||||||
| 03/07/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $22.76 | General |
| Category: ONCOLOGY | ||||||
| 02/06/2024 | Novartis Pharmaceuticals Corporation | Fabhalta (Drug) | Food and Beverage | In-kind items and services | $16.81 | General |
| Category: Immunology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 4 | 69 | 114 | $16,520 | $3,942 |
| 2022 | 1 | 85 | 209 | $33,440 | $33,405 |
| 2021 | 36 | 1,500 | 16,841 | $1.8M | $614,664 |
| 2020 | 38 | 1,447 | 18,705 | $2.5M | $751,580 |
Total Patients
3,101
Total Services
35,869
Medicare Billing
$1.4M
Procedure Codes
79
All Medicare Procedures & Services
79 procedure records from CMS Medicare Utilization — Page 1 of 4
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 30 | 39 | $14,550 | $3,295 | 22.6% |
| 80053 | Blood test, comprehensive group of blood chemicals | Office | 2023 | 13 | 29 | $918.72 | $289.80 | 31.5% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 13 | 27 | $629.37 | $197.86 | 31.4% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 13 | 19 | $421.65 | $159.60 | 37.9% |
| G9678 | Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation a | Office | 2022 | 85 | 209 | $33,440 | $33,405 | 99.9% |
| G9678 | Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation a | Office | 2021 | 222 | 1,235 | $197,600 | $197,803 | 100.1% |
| J0897 | Injection, denosumab, 1 mg | Office | 2021 | 27 | 10,080 | $622,550 | $165,384 | 26.6% |
| J2505 | Injection, pegfilgrastim, 6 mg | Office | 2021 | 11 | 38 | $308,798 | $80,801 | 26.2% |
| J1454 | Injection, fosnetupitant 235 mg and palonosetron 0.25 mg | Office | 2021 | 17 | 93 | $176,439 | $46,995 | 26.6% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 255 | 476 | $180,406 | $43,832 | 24.3% |
| 96413 | Infusion of chemotherapy into a vein up to 1 hour | Office | 2021 | 30 | 234 | $98,893 | $26,620 | 26.9% |
| 96367 | Infusion into a vein for therapy prevention or diagnosis additional sequential infusion up to 1 hour | Office | 2021 | 30 | 363 | $33,424 | $9,036 | 27.0% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 114 | 114 | $30,455 | $7,084 | 23.3% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 39 | 39 | $25,201 | $6,426 | 25.5% |
| 96417 | Infusion of different chemotherapy drug or substance into a vein up to 1 hour | Office | 2021 | 20 | 112 | $22,999 | $6,217 | 27.0% |
| 80053 | Blood test, comprehensive group of blood chemicals | Office | 2021 | 99 | 400 | $12,672 | $4,224 | 33.3% |
| 86300 | Immunologic analysis for detection of tumor antigen, quantitative; ca 15-3 | Office | 2021 | 46 | 153 | $9,552 | $3,184 | 33.3% |
| 82378 | Carcinoembryonic antigen (cea) protein level | Office | 2021 | 47 | 155 | $8,816 | $2,939 | 33.3% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2021 | 83 | 343 | $7,995 | $2,665 | 33.3% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis up to 1 hour | Office | 2021 | 21 | 35 | $7,359 | $1,938 | 26.3% |
| 96372 | Injection beneath the skin or into muscle for therapy, diagnosis, or prevention | Office | 2021 | 34 | 146 | $6,617 | $1,630 | 24.6% |
| 96375 | Injection of different drug or substance into a vein for therapy, diagnosis, or prevention | Office | 2021 | 17 | 105 | $6,090 | $1,393 | 22.9% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 15 | 19 | $3,963 | $1,015 | 25.6% |
| J3489 | Injection, zoledronic acid, 1 mg | Office | 2021 | 14 | 105 | $7,350 | $849.87 | 11.6% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2021 | 96 | 247 | $2,223 | $741.00 | 33.3% |
About Dr. Amy Lang, M.D
Dr. Amy Lang, M.D is a Medical Oncology healthcare provider based in San Antonio, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/10/2006. The National Provider Identifier (NPI) number assigned to this provider is 1104850486.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Amy Lang, M.D has received a total of $5,921 in payments from pharmaceutical and medical device companies, with $869.67 received in 2024. These payments were reported across 346 transactions from 32 companies. The most common payment nature is "Food and Beverage" ($5,388).
As a Medicare-enrolled provider, Lang has provided services to 3,101 Medicare beneficiaries, totaling 35,869 services with total Medicare billing of $1.4M. Data is available for 4 years (2020–2023), covering 79 distinct procedure/service records.
Ad
Practice Information
- Specialty Medical Oncology
- Location San Antonio, TX
- Active Since 07/10/2006
- Last Updated 07/11/2013
- Taxonomy Code 207RX0202X
- Entity Type Individual
- NPI Number 1104850486
Products in Payments
- KISQALI (Drug) $954.82
- IBRANCE (Drug) $696.32
- LYNPARZA (Drug) $516.07
- ZOLADEX (Drug) $322.88
- Neulasta (Biological) $318.72
- FASLODEX (Drug) $244.27
- SANCUSO (Drug) $221.55
- Nerlynx (Drug) $164.99
- VERZENIO (Drug) $158.50
- Enhertu (Drug) $143.48
- Prolia (Biological) $139.03
- FARESTON (Drug) $115.11
- Halaven (Drug) $113.52
- AKYNZEO (Drug) $113.15
- FOUNDATIONONE (Device) $96.47
- Lenvima (Drug) $92.24
- FERAHEME (Drug) $87.01
- PIQRAY (Drug) $81.51
- ENHERTU (Biological) $80.49
- LYNPARZA (Biological) $79.39
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Medical Oncology Doctors in San Antonio
Dr. Vijay Gunuganti, M.d, M.D
Medical Oncology — Payments: $1.8M
Medical Oncology $1.8M
Virginia Kaklamani, Md, MD
Medical Oncology — Payments: $905,581
Medical Oncology $905,581
Dr. John Sarantopoulos, M.d, M.D
Medical Oncology — Payments: $745,925
Medical Oncology $745,925
Dr. Anthony Tolcher
Medical Oncology — Payments: $250,389
Medical Oncology $250,389
Dr. Amita Patnaik, M.d, M.D
Medical Oncology — Payments: $150,997
Medical Oncology $150,997
Muralidhar Beeram, M.d, M.D
Medical Oncology — Payments: $119,186
Medical Oncology $119,186